United States · FDA National Drug Code directory
RELAFEN DS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 15370-170_48aa3640-1dd2-4693-9b0d-a99595b97a0e
- Product NDC
- 15370-170
- Form
- TABLET
- Composition / generic term
- NABUMETONE
- Labeler
- Carwin Pharmaceutical Associates, LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20190920
- Source listing expiry
- 20261231
Source-listed ingredients
- NABUMETONE — 1000 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 TABLET in 1 BOTTLE, PLASTIC (15370-170-10) · 15370-170-10
- 30 TABLET in 1 BOTTLE, PLASTIC (15370-170-30) · 15370-170-30
- 60 TABLET in 1 BOTTLE, PLASTIC (15370-170-60) · 15370-170-60
- 1 BLISTER PACK in 1 CARTON (15370-170-99) / 2 TABLET in 1 BLISTER PACK · 15370-170-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →